[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"labor-onset-and-length-abnormalities\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:labor-onset-and-length-abnormalities":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,80],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100528733","phase-2-use-of-cinnamomum-verum-for-induction-of-labor-double-blind-randomized-clinical-trial-100528733",false,"NCT06164613","Use of Cinnamomum Verum for Induction of Labor. Double Blind Randomized Clinical Trial","Use of Cinnamomum Verum Extract Versus Placebo for Induction of Labor and Reduction of Physiological Phase 2-3 of Labor. Double-blind Randomized Clinical Trial. CINNALAB TRIAL","CINNALAB","Inclusion Criteria:\n\n1. Delivery of an informed consent form signed and dated by parents or guardian and patient\n2. Declared willingness to comply with all study procedures and availability for the duration of the study.\n3. provision of appropriate consent and assent\n4. Willingness and ability to participate in study procedures\n5. Patients under 18 years of age\n6. Full-term pregnancies (37-41 Weeks of Gestation).\n7. Nulliparity\n8. Have your own cell phone\n9. Know how to read and write\n10. Residing in Tegucigalpa\n11. Be in good general health, as evidenced by your medical history\n12. Ultrasound with amniotic fluid index \\> 5 cm\n13. Non Stress Test Reactive\n14. Ability to take oral medication and be willing to comply with the cinnamon capsule regimen\n\nExclusion Criteria:\n\n1. Current use of antihypertensive or hypoglycemic medications\n2. Presence of non-curable chronic diseases prior to pregnancy or during pregnancy such as hypertension, diabetes, hypothyroidism\n3. Premature rupture of membranes\n4. Infections (urinary tract infection, chorioamnionitis) present at the time of the study (diagnosed with symptoms or leukocytes \\>12,500 or pathological urine examination)\n5. Allergies to cinnamaldehyde or cinnamon, canola oil\n6. Multiple pregnancy\n7. Major fetal malformations\n8. Fetal death\n9. Non-cephalic presentation\n10. Severe oligohydramnios (amniotic fluid index \\\u003C 2 cm)\n11. Having consumed or being consuming cinnamon products 7 days before the start of the study\n12. Febrile illness within 7 days before starting to take cinnamon\n13. Treatment with another investigational drug or other intervention within 7 days prior to the start of the intervention\n14. Current smoker or tobacco use",true,"FEMALE","14 Years","45 Years",{"count":22,"type":23},70,"ESTIMATED","INTERVENTIONAL",[26],"PHASE2","The purpose of the research protocol is to evaluate the effectiveness of Cinnamomum verum extract for the initiation of labor. Cinnamaldehyde ((E)-3-Phenylprop-2-enal) is an α, β unsaturated aromatic aldehyde, derived from cinnamon (Cinnamomum Verum oil) used as a flavoring; It is a clear yellowish liquid substance, with a strong odor and flavor. It is the main component of cinnamon (63%), giving it its physicochemical properties. Cinnamon has been an element of empirical use for the beginning of labor, however, its effectiveness has not been demonstrated.\n\nCinnamon has been reported for its ethnopharmacological properties in pregnancy, being used to facilitate childbirth, as a lactagogue and for postpartum recovery. In Honduras, its use has been reported to relieve nausea and vomiting during pregnancy, to reduce abdominal pain. , reduction of lower limb edema, to relieve anxiety during labor, as well as a lactagogue without convergent opinions.",[29,30],"Labor Onset and Length Abnormalities","First Birth",[32,33,34],"cinnamon oil, bark","labor onset","nulliparity","RECRUITING","2025-11-26",{"date":38,"type":39},"2025-12-04","ACTUAL",{"date":41,"type":39},"2023-12-04",{"date":43,"type":23},"2026-12-30",{"name":45,"class":46},"Universidad Nacional Autonoma de Honduras","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100500082","the-norwegian-world-health-organisation-labour-care-guide-trial-norwel-100500082","NCT05791630","The Norwegian World Health Organisation Labour Care Guide Trial (NORWEL)","The Norwegian World Health Organisation Labour Care Guide Trial","NORWEL","Inclusion Criteria:\n\n* Women in active labour\n* Labour and delivery at study sites\n\nExclusion Criteria:\n\n* None","18 Years",{"count":58,"type":23},23650,[60],"NA","Appropriate and timely care during birth is critical to the survival and health of women and their babies. In 2020, the World Health Organization (WHO) presented the Labour Care Guide (LCG) as the new recommended tool for monitoring birth and assessing progression, replacing the WHO partograph. This evidence-based guide was designed to ensure improved quality and safety of care, and to avoid unnecessary interventions during birth. The LCG was developed to be used in all settings globally, but it has only been tested in health facilities in South America, Asia and Africa, while it has not been tested in high-income settings. Implementing a new guideline for monitoring birth is a comprehensive operation that will affect both the national economy, health systems, and individual patients; therefore, further research on the possible advantages is needed before national enrolment. Hence, the trial proposed in this application is crucial to form the required foundation of knowledge. The trial will be conducted in labour wards at ten hospitals, covering all health regions in Norway, and the established Norwegian Research Network for Clinical Studies in Obstetrics (NORBIRTH), with dedicated local principal investigators, will provide a robust research environment. This trial will test the effect of the LCG. Results from this trial will provide knowledge needed to determine a future implementation of the LCG in Norway.",[63,64,29,65,66,67,68,69],"Labor Dystocia","Labor Complication","Labor (Obstetrics)--Complications","Experience, Life","Progression","Cesarean Section Complications","Apgar; 4-7 at 1 Minute","2025-04-02",{"date":72,"type":39},"2025-04-04",{"date":74,"type":39},"2025-04-01",{"date":76,"type":23},"2030-12-31",{"name":78,"class":46},"Ostfold Hospital Trust",10,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":17,"sex":18,"minAge":56,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":24,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100558155","papaverine-and-oxytocin-vs-oxytocin-alone-in-labor-induction-100558155","NCT06547437","Papaverine and Oxytocin vs Oxytocin Alone in Labor Induction","\"Evaluating the Effectiveness of Papaverine as an Adjunct to Oxytocin for Labor Induction: A Randomized Controlled Trial\"","Inclusion Criteria:\n\n* Women with a singleton pregnancy Over the age of 18 Term (between 37-42 weeks of gestation) A medical decision for labor induction using oxytocin. Cephalic presentation Viable fetus nulliparity\n\nExclusion Criteria:\n\n* parity \\>1\n* Twin pregnancy Women with a previous cesarean section Severe fetal anomalies Women with psychiatric disorders, including depression and schizophrenia. Contraindication to vaginal delivery Women unable to sign the consent form Women known to have SVT (supraventricular tachycardia). Women with a heart rate over 100 or arrhythmia Known sensitivity to any component of the drug Liver disease","50 Years",{"count":89,"type":23},126,[60],"This study aims to evaluate the efficacy and safety of combining papaverine with oxytocin for labor induction compared to oxytocin alone",[93,29],"Induced; Birth","NOT_YET_RECRUITING","2024-09-10",{"date":97,"type":39},"2024-09-19",{"date":99,"type":23},"2024-09",{"date":101,"type":23},"2025-12",{"name":103,"class":104},"Western Galilee Hospital-Nahariya","OTHER_GOV"]